Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis

By sjmartinez • September 8, 2023

Kulkarni AV, Tevethia H, Kumar K, Premkumar M, Muttaiah MD, Hiraoka A, Hatanaka T, Tada T, Kumada T, Kakizaki S, Vogel A, Finn RS, Rao PN, Pillai A, Reddy DN, Singal AG. Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. EClinicalMedicine. 2023 Aug 30;63:102179. doi: 10.1016/j.eclinm.2023.102179. PMID: 37680945; PMCID: PMC10480543.

Tags: Adverse events, Hematology/Oncology, immunotherapy, liver cancer, Publications, Radiological response

Related Posts

Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset

Nishio M, Seto T, Reck M, Garon EB, Nishio K, Kasahara K, Nishino K, Satouchi M, Yoh K, Hayashi H, Sakai K, Enatsu S, Frimodt-Møller[...]

Adequacy of Immune Checkpoint Inhibitor-Associated Thyroid Function Monitoring After Therapy

Velez MA, Kang ES, Thompson CA, Lind-Lebuffe J, Shen C, Park SJ, Han A, Gower A, Li D, Rochigneux P, Grogan TR, Elashoff DA, Garon[...]

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer

Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, Hyung WJ, Wyrwicz L, Oh DY, Omori T, Moehler M, Garrido M,[...]